Biosensors International

TriMed Staff | | Cardiovascular Business | Patient Care
Biosensors International (Booth 1456) is featuring clinical data for its BioMatrix Biolimus A9, its new bioresorbable drug-eluting stent platform, which is not yet available in the U.S.

BioMatrix is mounted on a low-profile delivery system enabling access to difficult lesions and vessel physiologies. In combination with its proprietary drug, Biolimus A9, has a bioresorbable polylactic acid polymer coating which is co-released with Biolimus A9, reaching therapeutic concentrations during therapeutic window when cells are proliferating. The Biolimus A9 is eluted from bioabsorbable PLA-coated stent in de novo coronary lesions.

TriMed Staff

Related Content

Concomitant ablation surgery during heart operations boosts long-term survival
Cardiologist explores why colchicine failed to help heart attack patients
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Most heart failure patients miss out on guideline-recommended palliative care
Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes
FDA approves Medtronic’s new all-in-one mapping and ablation system for AFib

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.